Capital Bank & Trust’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Capital Bank & Trust’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-68,262	Closed	-$6.63M	–	204
2021 Q2	$6.63M	Buy	68,262 +1,108	+2%	+$89.9K	0.08%	144
2021 Q1	$4.59M	Buy	67,154 +2,044	+3%	+$165K	0.05%	158
2020 Q4	$5.58M	Buy	65,110 +1,852	+3%	+$157K	0.07%	146
2020 Q3	$4.11M	Buy	63,258 +757	+1%	+$49.6K	0.06%	144
2020 Q2	$4.57M	Buy	62,501 +1,658	+3%	+$88.2K	0.07%	143
2020 Q1	$2.07M	Buy	+60,843	New	+$2.78M	0.03%	166

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Bank & Trust's BHVN Position: Q3 2021 in Review

Capital Bank & Trust sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2021, closing a stake of 68,262 shares — an estimated $6.63M sold.

Capital Bank & Trust first reported a position in BHVN in Q1 2020 and held it in 6 quarters. The position peaked at $6.63M in Q2 2021. 249 funds tracked by Wall St. Rank hold BHVN as of Q3 2021.

Capital Bank & Trust reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2021 after selling out during the quarter.
Capital Bank & Trust sold 68,262 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2021, an estimated $6.63M.
Capital Bank & Trust first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 6 quarters.
Capital Bank & Trust's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6.63M in Q2 2021.
249 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2021.

Based on Capital Bank & Trust's 13F filing for Q3 2021, filed 15 Nov 2021.